TY - JOUR
T1 - Circulating adhesion molecules and subclinical interstitial lung disease
T2 - The Multi-Ethnic Study of Atherosclerosis
AU - McGroder, Claire F.
AU - Aaron, Carrie P.
AU - Bielinski, Suzette J.
AU - Kawut, Steven M.
AU - Tracy, Russell P.
AU - Raghu, Ganesh
AU - Barr, R. Graham
AU - Lederer, David J.
AU - Podolanczuk, Anna J.
N1 - Funding Information:
Conflict of interest: C.F. McGroder has nothing to disclose. C.P. Aaron reports grants from NIH, during the conduct of the study; grants from Alpha-1 Foundation and Stony-Wold Herbert Fund, Inc., personal fees from Lancet Respiratory Medicine, outside the submitted work. S.J. Bielinski reports a grant from NIH, during the conduct of the study. S.M. Kawut reports grants from NIH, during the conduct of the study; non-financial (travel) support from ATS and the Pulmonary Hypertension Association, grants for education from Actelion, United Therapeutics, Gilead, Lung Biotech, Bayer and Mallinkrodt, grants and non-financial support from Cardiovascular Medical Research and Education Fund, outside the submitted work; and has served in an advisory capacity (for grant review and other purposes) for United Therapeutics, Akros Pharmaceuticals, GlaxoSmithKline and Complexa, Inc. without financial support or in-kind benefits. R.P. Tracy reports grants from NIH, during the conduct of the study. G. Raghu has nothing to disclose. R.G. Barr has nothing to disclose. D.J. Lederer reports personal fees for steering committee work from Roche and Galapagos, personal fees for advisory board work from Sanofi Genzyme and Philips Respironics, grants and personal fees for advisory board work and consultancy from Fibrogen, Global Blood Therapeutics and Boehringer Ingelheim, and fees for consultancy paid directly to Columbia University from Pulmonary Fibrosis Foundation, outside the submitted work; since May 2018, D.J. Lederer no longer receives fees from industry sources. A.J. Podolanczuk has nothing to disclose.
Funding Information:
Support statement: This work was funded by the US Department of Health and Human Services, National Institutes of Health (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169). Funding information for this article has been deposited with the Crossref Funder Registry.
Publisher Copyright:
Copyright © ERS 2019
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Adhesion molecules may contribute to the development of interstitial lung disease (ILD) and have been proposed as prognostic biomarkers in idiopathic pulmonary fibrosis. Our objective was to determine whether the circulating adhesion molecules soluble intracellular adhesion molecule (sICAM)-1, soluble vascular cell adhesion molecule (sVCAM)-1 and P-selectin are associated with subclinical ILD in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis enrolled males and females aged 45-84 years from six communities in the United States in 2000-2002. High attenuation areas were defined as the percentage of imaged lung volume with attenuation −600-−250 HU on cardiac computed tomography (CT). Interstitial lung abnormalities were visually assessed on full-lung CT. Spirometry was performed on a subset of individuals. ILD hospitalisations and deaths were adjudicated. In fully adjusted analyses, higher levels of sICAM-1, sVCAM-1 and P-selectin were associated with greater high attenuation areas (2.94%, 95% CI 1.80-4.07%; 1.24%, 95% CI 0.14-2.35%; and 1.58%, 95% CI 0.92-2.23%, respectively), and greater rate of ILD hospitalisations (HR 1.36, 95% CI 1.03-1.80; 1.40, 95% CI 1.07-1.85; and 2.03, 95% CI 1.16-3.5, respectively). sICAM-1 was associated with greater prevalence of interstitial lung abnormalities (OR 1.39, 95% CI 1.13-1.71). sICAM-1 and P-selectin were associated with lower forced vital capacity (44 mL, 95% CI 12-76 mL and 29 mL, 95% CI 8-49 mL, respectively). sVCAM-1 and P-selectin were associated with increased risk of ILD death (HR 2.15, 95% CI 1.26-3.64 and 3.61, 95% CI 1.54-8.46, respectively). Higher levels of circulating sICAM-1, sVCAM-1 and P-selectin are independently associated with CT and spirometric measures of subclinical ILD, and increased rate of adjudicated ILD events among community-dwelling adults.
AB - Adhesion molecules may contribute to the development of interstitial lung disease (ILD) and have been proposed as prognostic biomarkers in idiopathic pulmonary fibrosis. Our objective was to determine whether the circulating adhesion molecules soluble intracellular adhesion molecule (sICAM)-1, soluble vascular cell adhesion molecule (sVCAM)-1 and P-selectin are associated with subclinical ILD in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis enrolled males and females aged 45-84 years from six communities in the United States in 2000-2002. High attenuation areas were defined as the percentage of imaged lung volume with attenuation −600-−250 HU on cardiac computed tomography (CT). Interstitial lung abnormalities were visually assessed on full-lung CT. Spirometry was performed on a subset of individuals. ILD hospitalisations and deaths were adjudicated. In fully adjusted analyses, higher levels of sICAM-1, sVCAM-1 and P-selectin were associated with greater high attenuation areas (2.94%, 95% CI 1.80-4.07%; 1.24%, 95% CI 0.14-2.35%; and 1.58%, 95% CI 0.92-2.23%, respectively), and greater rate of ILD hospitalisations (HR 1.36, 95% CI 1.03-1.80; 1.40, 95% CI 1.07-1.85; and 2.03, 95% CI 1.16-3.5, respectively). sICAM-1 was associated with greater prevalence of interstitial lung abnormalities (OR 1.39, 95% CI 1.13-1.71). sICAM-1 and P-selectin were associated with lower forced vital capacity (44 mL, 95% CI 12-76 mL and 29 mL, 95% CI 8-49 mL, respectively). sVCAM-1 and P-selectin were associated with increased risk of ILD death (HR 2.15, 95% CI 1.26-3.64 and 3.61, 95% CI 1.54-8.46, respectively). Higher levels of circulating sICAM-1, sVCAM-1 and P-selectin are independently associated with CT and spirometric measures of subclinical ILD, and increased rate of adjudicated ILD events among community-dwelling adults.
UR - http://www.scopus.com/inward/record.url?scp=85072791249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072791249&partnerID=8YFLogxK
U2 - 10.1183/13993003.00295-2019
DO - 10.1183/13993003.00295-2019
M3 - Article
C2 - 31371443
AN - SCOPUS:85072791249
SN - 0903-1936
VL - 54
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
M1 - 1900295
ER -